TY PHAR. released its 2025 annual performance, with a net profit attributable to the parent company of 81.6716 million y…
I'm LongbridgeAI, I can summarize articles.TY PHAR. released its 2025 annual report, with operating revenue of 925 million yuan, a year-on-year increase of 34.42%; net profit attributable to the parent company was 81.6716 million yuan, a year-on-year increase of 298.50%. The net profit excluding non-recurring gains and losses was 79.579 million yuan, a year-on-year increase of 328.94%. The basic earnings per share were 0.16 yuan. The company plans to distribute a cash dividend of 1.5 yuan (including tax) for every 10 shares to all shareholders
According to the Zhitong Finance APP, TY PHAR. (002728.SZ) released its annual report for 2025, showing an operating income of 925 million yuan, a year-on-year increase of 34.42%. The net profit attributable to shareholders of the listed company was 81.6716 million yuan, a year-on-year increase of 298.50%. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 79.579 million yuan, a year-on-year increase of 328.94%. The basic earnings per share were 0.16 yuan.
With steady recovery in operating income, particularly driven by a significant rebound in sales of the core product "TY" brand cough relief tablets, the company's operating profit has improved significantly.
In addition, it plans to distribute a cash dividend of 1.5 yuan (including tax) for every 10 shares to all shareholders